Polyethylene glycol interferon α-2b-induced immune-mediated polyradiculoneuropathy

Internal Medicine

Volumn 48, Issue 7, 2009, Pages 569-572

  Kato Motozaki, Yuko ^a   Komai, Kiyonobu ^a,b   Takahashi, Kazuya ^a   Ishida, Chiho ^a,b   Ueda, Masami ^c   Kusunoki, Susumu ^c   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b National Hospital Organization Iou National Hospital   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti ganglioside antibody; Hepatitis C infection; Pegylated interferon alpha; Polyradiculoneuropathy

Indexed keywords

GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN M; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FILTRATION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; POLYRADICULONEUROPATHY; SYMPTOM;

ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DRUG CARRIERS; DRUG THERAPY, COMBINATION; G(M1) GANGLIOSIDE; GAIT DISORDERS, NEUROLOGIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MUSCLE WEAKNESS; PLASMAPHERESIS; POLYETHYLENE GLYCOLS; POLYRADICULONEUROPATHY; RIBAVIRIN;

EID: 67650047688     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1794     Document Type: Article

References (17)

1. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33: 433-438, 2001.
2. Marzo ME, Tintore M, Fabregues O, Montalban X, Codina A. Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-α. J Neurol Neurosurg Psychiatry 65: 604, 1998.
3. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis Cassociated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 25: 909-913, 2002.
4. Negoro K, Fukusako T, Morimatsu M, Liao CM. Acute axonal polyneuropathy during interferon α-2A therapy for chronic hepatitis type C. Muscle Nerve 17: 1351-1352, 1994.
5. Beuthien W, Mellinghoff HU, Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 24: 507-515, 2005.
6. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-α. Muscle Nerve 23: 433-435, 2000.
7. Briani C, Chemello L, Zara G, et al. Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology 67: 781-785, 2006.
8. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 35: 570-576, 1994.
9. Ilyas AA, Mithen FA, Chen ZW, Cook SD. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barre syndrome. J Neurol Sci 102: 67-75, 1991.
10. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43: 537-544, 1993.
11. McCombe PA, Wilson R, Prentice RL. Anti-ganglioside antibodies in peripheral neuropathy. Clin Exp Neurol 29: 182-188, 1992.
12. Yato M, Ohkoshi N, Sato A, Shoji S, Kusunoki S. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Eur J Neurol 7: 227-230, 2000.
13. Ogawa-Goto K, Ohta Y, Kubota K, et al. Glycosphingolipids of human peripheral nervous system myelins isolated from cauda equina. J Neurochem 61: 1398-1403, 1993.
14. van Schaik IN, Vermeulen M, van Doorn PA, Brand A. Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg). J Neuroimmunol 54: 109-115, 1994.
15. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 49: 1289-1292, 1997.
16. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48: 624-631, 2000.
17. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204: 9-26, 2005.